PMED — Peptonic Medical AB Income Statement
0.000.00%
- SEK23.04m
- SEK22.65m
- SEK26.89m
Annual income statement for Peptonic Medical AB, fiscal year end - December 31st, SEK millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | Interim Report | ARS | ARS | ARS | PRESS |
Standards: | — | SAS | SAS | SAS | — |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 35.2 | 31.6 | 43.6 | 37.1 | 26.9 |
Cost of Revenue | |||||
Gross Profit | 21.1 | 19.1 | 23.4 | 16.3 | 15.2 |
Selling / General / Administrative Expenses | |||||
Depreciation and Amortization | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 68.2 | 105 | 77.2 | 78.3 | 85.5 |
Operating Profit | -33 | -73.7 | -33.6 | -41.2 | -58.6 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -34.2 | -73.7 | -36.9 | -42.6 | -60 |
Provision for Income Taxes | |||||
Net Income After Taxes | -34.2 | -73.7 | -36.9 | -42.6 | -60 |
Net Income Before Extraordinary Items | |||||
Net Income | -34.2 | -73.7 | -36.9 | -42.6 | -60 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -34.2 | -73.7 | -36.9 | -42.6 | -60 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.087 | -0.124 | -0.072 | -0.021 | -0.016 |
Dividends per Share |